This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): tirofiban hydrochloride intravenous injection, Agrastat
BioMedTracker has separate drug profiles for the intravenous and transdermal forumations of tirofiban. Please also see Transdermal Tirofiban.
Aggrastat inhibits platelet glycoprotein (GP) IIb/IIIa receptors to prevent platelet aggregation.
Guilford and Merck
Guilford acquired US rights to Aggrastat from Merck in 2003. Merck retains rights in the rest of the world. From October 2003 until December 31, 2006, the agreement provides that Merck will not receive royalty payments on net revenue less than $40.0 million. On net revenue above $40.0 million prior to December 31, 2006 and beginning on January 1, 2007, on all revenue from Aggrastat, Merck will receive royalty payments ranging from 5% to 20% of Aggrastat net revenue, based upon Guilford's achievement of certain net revenue thresholds.
On October 3, 2005, MGI Pharma closed its previously-announced acquisition of Guilford Pharmaceuticals Inc.
Medicure and Merck
In August 2006, Medicure acquired the exclusive U.S. rights to Aggrastat Injection from MGI Pharma. Merck continues to market Aggrastat outside the U.S. Under the terms of the agreement Medicure will pay MGI Pharma $19 million plus the purchase of existing inventory, and will make...See full deal structure in Biomedtracker
Partners: Merck & Co., Inc. Biotoscana International Cardiome Pharma Corp. AOP Orphan Pharmaceuticals AG
Aggrastat Injection News
Additional information available to subscribers only: